Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Ascorbic Acid in Non-APL AML
NCT00184054Phase 2Terminated
- Sponsor
- University of Southern California
- Start
- Apr 2002
- Primary completion
- Jun 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute myeloid leukemia (AML), sponsored by University of Southern California. Primary endpoint: Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)) up to 1 year. Started Apr 2002; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00184054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00184054.